title: Leptospira interrogans icterohaemorrhagiae in a patient with Crohn's disease.
authors.forename: Konstantinos H
authors.initials: KH
authors.lastname: Katsanos
authors.forename: Konstantinos P
authors.initials: KP
authors.lastname: Katopodis
authors.forename: Maria
authors.initials: M
authors.lastname: Kosmidou
authors.forename: Konstantinos C
authors.initials: KC
authors.lastname: Siamopoulos
authors.forename: Epameinondas V
authors.initials: EV
authors.lastname: Tsianos
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D041383:Leptospira interrogans serovar icterohaemorrhagiae / Q000302:isolation & purification*; D007922:Leptospirosis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D002443:Ceftriaxone; D000069285:Infliximab; D000637:Transaminases